Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Relapse Prevention in Children with Disruptive Behavior
NCT00236444Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2001
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in conduct disorder (CD), oppositional defiant disorder (ODD), Disruptive behavior disorders (DBD), sponsored by Johnson & Johnson. Started Dec 2001; status: completed.
02
Drugs
risperidone
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT00236444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236444.